Видео с ютуба Mitapivat

Hanny Al-Samkari: Mitapivat for Patients With Pyruvate Kinase Deficiency

Insights into the mechanism of action and applications of mitapivat

Mitapivat improves work/school attendance in patients with pyruvate kinase deficiency

FDA właśnie zatwierdziła tabletkę na talasemię i to zmienia zasady gry

Results from the Phase III RISE UP study investigating mitapivat in sickle cell disease

Луспатерцепт и Митапиват для лечения наследственных анемий

SATISFY: mitapivat in patients with erythrocyte membranopathies

The promise of pyruvate kinase activators, such as mitapivat, for treating SCD and thalassemia

What you NEED to know about MOA of PYRUKYND (mitapivat) -- approved for PK Deficiency Anemia

Mitapivat for Thalassemia: How AQVESME Works to Reduce Anemia and Blood Transfusions

mitapivat-Gamechanger medicine in Hemolytic anemia/Thalassemia patients?

An update on the ENERGIZE-T trial of mitapivat in transfusion-dependent thalassemia

Updates from the ENERGIZE study of mitapivat in non-transfusion-dependent alpha-/beta-thalassemia

Mitapivat: mechanism of action and updates with this agent in thalassemia treatment

Update on the ENERGIZE trial of mitapivat in NTD alpha- and beta-thalassemia

Agios Pharmaceuticals FDA Approves AQVESME™ (mitapivat) for the Treatment of Anemia | Dec 24, 2025

Advances in pyruvate kinase activators for MDS and PKD: mitapivat & AG946

Mechanism of action of mitapivat and its potential in the treatment of SCD

ENERGIZE-T: a Phase III study of mitapivat in transfusion-dependent alpha- or beta-thalassemia

Mitapivat increases β-thalassemic erythroblast energy production and oxidative stress responsiveness